Skip to main content
main-content

01.12.2012 | Research | Ausgabe 1/2012 Open Access

Molecular Cancer 1/2012

Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium

Zeitschrift:
Molecular Cancer > Ausgabe 1/2012
Autoren:
Stefanie Aust, Anna Bachmayr-Heyda, Petra Pateisky, Dan Tong, Silvia Darb-Esfahani, Carsten Denkert, Radoslav Chekerov, Jalid Sehouli, Sven Mahner, Toon Van Gorp, Ignace Vergote, Paul Speiser, Reinhard Horvat, Robert Zeillinger, Dietmar Pils
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1476-4598-11-69) contains supplementary material, which is available to authorized users.

Conflicts of interests

The authors have no conflicts of interest to declare.

Abstract

Background

The role of the tumor necrosis factor receptor associated protein 1 (TRAP1) – supposed to be involved in protection of cells from apoptosis and oxidative stress – has just started to be investigated in ovarian cancer. TRAP1 has been shown to be estrogen up-regulated in estrogen receptor α (ERα) positive ovarian cancer cells. The clinical impact of TRAP1 is not clear so far and the significance of ERα expression as therapeutic and prognostic marker is still controversial. Therefore, we investigated the importance of TRAP1 together with ERα in regard to clinicopathological parameters, chemotherapy response, and survival.

Methods and results

Expressions of TRAP1 and ERα were evaluated by immunohistochemical staining of tissue microarrays comprised of 208 ovarian cancer samples. TRAP1 was highly expressed in 55% and ERα was expressed in 52% of all cases. High TRAP1 expression correlated significantly with ERα (p < 0.001) but high TRAP1 expression was also found in 42% of ERα negative cases. High TRAP1 expression correlated significantly with favorable chemotherapy-response (HR = 0.48; 95%CI 0.24-0.96, p=0.037) and showed a significant impact on overall survival (OS) (HR = 0.65; 95%CI 0.43-0.99, p = 0.044). ERα expression was a favorable prognostic factor for OS in univariate and multivariate analyses. Interestingly, the combined pattern (ERα positive and/or TRAP1-high) revealed the strongest independent and significant positive influence on OS (HR = 0.41; 95%CI 0.27-0.64).

Conclusion

Immunohistochemical evaluation of TRAP1 together with ERα provides significant prognostic information. TRAP1 alone is significantly associated with chemotherapy response and overall survival, rendering TRAP1 as interesting scientific and therapeutic target.
Zusatzmaterial
Additional file 1: Supplementary data. (DOCX 2 MB)
12943_2012_1057_MOESM1_ESM.docx
Authors’ original file for figure 1
12943_2012_1057_MOESM2_ESM.tiff
Authors’ original file for figure 2
12943_2012_1057_MOESM3_ESM.tiff
Authors’ original file for figure 3
12943_2012_1057_MOESM4_ESM.pdf
Authors’ original file for figure 4
12943_2012_1057_MOESM5_ESM.pdf
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2012

Molecular Cancer 1/2012 Zur Ausgabe

Neu im Fachgebiet Onkologie


 

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise